Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.

Venneker S, Kruisselbrink AB, Briaire-de Bruijn IH, de Jong Y, van Wijnen AJ, Danen EHJ, Bovée JVMG.

Cancers (Basel). 2019 Dec 2;11(12). pii: E1918. doi: 10.3390/cancers11121918.

2.

Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.

Lam SW, Cleven AHG, Kroon HM, Briaire-de Bruijn IH, Szuhai K, Bovée JVMG.

Virchows Arch. 2019 Nov 25. doi: 10.1007/s00428-019-02684-9. [Epub ahead of print]

PMID:
31768625
3.

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.

Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.

4.

Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas.

van IJzendoorn DGP, Szuhai K, Briaire-de Bruijn IH, Kostine M, Kuijjer ML, Bovée JVMG.

PLoS Comput Biol. 2019 Feb 20;15(2):e1006826. doi: 10.1371/journal.pcbi.1006826. eCollection 2019 Feb.

5.

Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.

Kostine M, Briaire-de Bruijn IH, Cleven AHG, Vervat C, Corver WE, Schilham MW, Van Beelen E, van Boven H, Haas RL, Italiano A, Cleton-Jansen AM, Bovée JVMG.

Oncoimmunology. 2017 Oct 26;7(2):e1386828. doi: 10.1080/2162402X.2017.1386828. eCollection 2018.

6.

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.

Cleven AHG, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM, Cleton-Jansen AM, Bovée JVMG.

Clin Sarcoma Res. 2017 May 4;7:8. doi: 10.1186/s13569-017-0074-6. eCollection 2017.

7.

Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

de Jong Y, van Maldegem AM, Marino-Enriquez A, de Jong D, Suijker J, Briaire-de Bruijn IH, Kruisselbrink AB, Cleton-Jansen AM, Szuhai K, Gelderblom H, Fletcher JA, Bovée JV.

Lab Invest. 2016 Oct;96(10):1128-37. doi: 10.1038/labinvest.2016.91. Epub 2016 Sep 12.

8.

Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers.

Hoekstra AS, Addie RD, Ras C, Seifar RM, Ruivenkamp CA, Briaire-de Bruijn IH, Hes FJ, Jansen JC, Corssmit EP, Corver WE, Morreau H, Bovée JV, Bayley JP, Devilee P.

Hum Mol Genet. 2016 Sep 1;25(17):3715-3728. doi: 10.1093/hmg/ddw218. Epub 2016 Jul 8.

PMID:
27402879
9.

Multimodal Mass Spectrometry Imaging of N-Glycans and Proteins from the Same Tissue Section.

Heijs B, Holst S, Briaire-de Bruijn IH, van Pelt GW, de Ru AH, van Veelen PA, Drake RR, Mehta AS, Mesker WE, Tollenaar RA, Bovée JV, Wuhrer M, McDonnell LA.

Anal Chem. 2016 Aug 2;88(15):7745-53. doi: 10.1021/acs.analchem.6b01739. Epub 2016 Jul 14.

PMID:
27373711
10.

Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.

Riester SM, Torres-Mora J, Dudakovic A, Camilleri ET, Wang W, Xu F, Thaler RR, Evans JM, Zwartbol R, Briaire-de Bruijn IH, Maran A, Folpe AL, Inwards CY, Rose PS, Shives TC, Yaszemski MJ, Sim FH, Deyle DR, Larson AN, Galindo MA, Cleven AGH, Oliveira AM, Cleton-Jansen AM, Bovée JVMG, van Wijnen AJ.

J Orthop Res. 2017 May;35(5):1137-1146. doi: 10.1002/jor.23344. Epub 2016 Jun 28.

11.

Linkage-Specific in Situ Sialic Acid Derivatization for N-Glycan Mass Spectrometry Imaging of Formalin-Fixed Paraffin-Embedded Tissues.

Holst S, Heijs B, de Haan N, van Zeijl RJ, Briaire-de Bruijn IH, van Pelt GW, Mehta AS, Angel PM, Mesker WE, Tollenaar RA, Drake RR, Bovée JV, McDonnell LA, Wuhrer M.

Anal Chem. 2016 Jun 7;88(11):5904-13. doi: 10.1021/acs.analchem.6b00819. Epub 2016 May 23.

PMID:
27145236
12.

Histology-Guided High-Resolution Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging.

Heijs B, Abdelmoula WM, Lou S, Briaire-de Bruijn IH, Dijkstra J, Bovée JV, McDonnell LA.

Anal Chem. 2015 Dec 15;87(24):11978-83. doi: 10.1021/acs.analchem.5b03610. Epub 2015 Dec 4.

PMID:
26595321
13.

Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.

Hoekstra AS, de Graaff MA, Briaire-de Bruijn IH, Ras C, Seifar RM, van Minderhout I, Cornelisse CJ, Hogendoorn PC, Breuning MH, Suijker J, Korpershoek E, Kunst HP, Frizzell N, Devilee P, Bayley JP, Bovée JV.

Oncotarget. 2015 Nov 17;6(36):38777-88. doi: 10.18632/oncotarget.6091.

14.

A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization.

de Graaff MA, de Jong D, Briaire-de Bruijn IH, Hogendoorn PC, Bovée JV, Szuhai K.

Cancer Genet. 2015 Nov;208(11):537-44. doi: 10.1016/j.cancergen.2015.07.005. Epub 2015 Jul 31.

PMID:
26361850
15.

Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4.

Martins-Neves SR, Corver WE, Paiva-Oliveira DI, van den Akker BE, Briaire-de-Bruijn IH, Bovée JV, Gomes CM, Cleton-Jansen AM.

J Cell Physiol. 2016 Apr;231(4):876-86. doi: 10.1002/jcp.25179. Epub 2015 Sep 9.

PMID:
26332365
16.

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.

Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, Riester SM, Dudakovic A, Danen E, Cleton-Jansen AM, van Wijnen AJ, Bovée JV.

Oncotarget. 2015 May 20;6(14):12505-19.

17.

NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.

Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH, Somaiah N, Bovée JV, Lazar AJ, Nielsen TO.

Mod Pathol. 2015 Apr;28(4):587-95. doi: 10.1038/modpathol.2014.155. Epub 2014 Nov 21.

18.

Evaluation of prognostic indicators using validated canine insulinoma tissue microarrays.

Buishand FO, Visser J, Kik M, Gröne A, Keesler RI, Briaire-de Bruijn IH, Kirpensteijn J.

Vet J. 2014 Jul;201(1):57-63. doi: 10.1016/j.tvjl.2014.05.004. Epub 2014 May 6.

PMID:
24878267
19.

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM.

BMC Cancer. 2013 May 20;13:245. doi: 10.1186/1471-2407-13-245.

20.

Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.

Willems SM, Schrage YM, Bruijn IH, Szuhai K, Hogendoorn PC, Bovée JV.

Mol Cancer. 2010 Sep 23;9:257. doi: 10.1186/1476-4598-9-257.

Supplemental Content

Loading ...
Support Center